Press Release
August 2, 2021

Alnylam and PeptiDream to Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics, PeptiDream to Potentially Receive Up to $2.2 Billion in Milestones

The Life Sciences team advised Alnylam Pharmaceuticals (Nasdaq: ALNY) in its license and collaboration agreement with PeptiDream (Tokyo Stock Exchange: 4587) to discover and develop peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tissues outside the liver. Through this collaboration, the companies will collaborate to select and optimize peptides for targeted delivery of small interfering RNA (siRNA) molecules to a wide range of cell types and tissues via specific interactions with receptors expressed on the target cells.

Under the terms of the agreement, PeptiDream will receive an upfront payment from Alnylam as well as R&D funding over the term of the research collaboration, as provided in the agreement. PeptiDream may also receive payments based on the achievement of specified development, regulatory, and commercial milestones potentially totaling up to $2.2 billion (¥244 billion*1). In addition, PeptiDream is eligible to receive low-to-mid single digit royalties on sales on any such Alnylam products.

Founded in 2002, Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. 

The Goodwin team was led by Sarah Solomon and Shannyn Henke with invaluable assistance from Dan Karelitz, Alexandra Haas and summer associate Liz Caruso.

For additional details on the collaboration, please read the press release and coverage in FierceBiotech.